Abstract | BACKGROUND: METHODS: We retrospectively reviewed the records of all children diagnosed with opsoclonus-myoclonus syndrome at BC Children's Hospital from 2000 to 2010. Neurological outcomes were compared with those previously reported in the literature. RESULTS: CONCLUSIONS: Most patients in this series were treated with early multimodal immunotherapy, and neurological outcomes were better than those in most historical reports. This finding is consistent with recent studies that suggest multimodal immunotherapy regimens may be improving the prognosis in this challenging disease. However, some individuals did well with less aggressive treatment, and further studies are required to determine optimal treatment approach.
|
Authors | Armine Galstyan, Colin Wilbur, Kathryn Selby, Juliette Hukin |
Journal | Pediatric neurology
(Pediatr Neurol)
Vol. 72
Pg. 65-69
(Jul 2017)
ISSN: 1873-5150 [Electronic] United States |
PMID | 28479124
(Publication Type: Journal Article)
|
Copyright | Copyright © 2017 Elsevier Inc. All rights reserved. |
Chemical References |
- Adrenal Cortex Hormones
- Immunoglobulins, Intravenous
- Immunosuppressive Agents
- Prednisone
|
Topics |
- Adrenal Cortex Hormones
(therapeutic use)
- Child, Preschool
- Female
- Humans
- Immunoglobulins, Intravenous
(therapeutic use)
- Immunosuppressive Agents
(therapeutic use)
- Infant
- Male
- Opsoclonus-Myoclonus Syndrome
(diagnosis, drug therapy)
- Prednisone
(therapeutic use)
- Prognosis
- Retrospective Studies
- Treatment Outcome
|